FDA ‘green list’ flagging illegal GLP-1RA compounders is long overdue
In the midst of the rising popularity of glucagon-like peptide-1 receptor agonists (GLP-1RAs), and their compounded versions, the US Food …
Post
-
-
Podcast: The FDA’s emerging aversion to advisory committees
Last month, the head of the US Food and Drug Administration's (FDA) Centre for Drug Evaluation and Research (CDER) George …
-
BMS expands CAR-T portfolio with $1.5bn Orbital buyout
Bristol Myers Squibb (BMS) has agreed to acquire CAR-T specialist Orbital Therapeutics for $1.5bn, adding several RNA-based therapies to the …
-
AstraZeneca sets $4.5bn Virginia API plant construction in motion
AstraZeneca has commenced construction of its $4.5bn active pharmaceutical ingredient (API) manufacturing facility in Virginia. The site, which is located near …
-
Flu vaccine uptake increases 28% in England
The number of people receiving a flu vaccine across England has increased by over a quarter, as cases of both …
-
Podcast: The FDA’s emerging aversion to advisory committees
Last month, the head of the US Food and Drug Administration's (FDA) Centre for Drug Evaluation and Research (CDER) George …
-
BMS expands CAR-T portfolio with $1.5bn Orbital buyout
Bristol Myers Squibb (BMS) has agreed to acquire CAR-T specialist Orbital Therapeutics for $1.5bn, adding several RNA-based therapies to the …
-
AstraZeneca sets $4.5bn Virginia API plant construction in motion
AstraZeneca has commenced construction of its $4.5bn active pharmaceutical ingredient (API) manufacturing facility in Virginia. The site, which is located near …
-
Flu vaccine uptake increases 28% in England
The number of people receiving a flu vaccine across England has increased by over a quarter, as cases of both …
-
FDA approves Celltrion’s Eydenzelt for eye diseases
Celltrion has received approval from the US Food and Drug Administration (FDA) for the biosimilar product, Eydenzelt (aflibercept-boav), to treat …
-
Pharma R&D set to endure despite rising MFN costs
Pharmaceutical research and development (R&D) is unlikely to be significantly impacted by most favored nation (MFN) pricing, according to industry …
-
Turbine and AstraZeneca partner for ADC discovery
Turbine and AstraZeneca have entered a partnership to enhance the discovery of antibody-drug conjugates (ADCs) using the former’s virtual disease …
-
Boehringer’s Jascayd nets first FDA IPF approval in over 10 years
Boehringer Ingelheim’s Jascayd (nerandomalist) has got the US Food and Drug Administration (FDA) nod in idiopathic pulmonary fibrosis (IPF), making …
-
Novo Nordisk buys MASH specialist Akero for up to $5.2bn
Novo Nordisk has agreed to buy Akero Therapeutics in a deal rising to a potential $5.2bn, as the Danish drugmaker …
-
Amazon Pharmacy kiosks to provide prescription medications in minutes
Amazon Pharmacy is set to launch kiosks filled with prescription medicines that will allow patients to pick up prescriptions immediately …
